Fibrin Monomer Compared With Hemostatic Sponge in the Integrity of the Graft During Tympanoplasty

Overview

The diagnosis of tympanic perforation reaches a high number of records in otorhinolaryngology services worldwide. Most of the tympanoplasties are performed in patients whose cause of perforation and hearing loss was chronic otitis media; this entity affects the population between 0.5 to 30% , the statistics mention more than 20 million people with this disease in the world. Since the introduction of tympanoplasty in the second half of the nineteenth century there have been numerous publications nationally and internationally about various experiences and new techniques. Including the use of fibrin monomer . This procedure is usually performed with the use of hemostatic sponge and recently with fibrin monomer, both materials are part of the basic input and surgical hemostatic agents. In this hospital are performed on average 110 tympanoplasty per year which has a percentage of non- integrity of the graft in the case of microscopic tympanoplasties using hemostatic sponge of 16% which is similar to the index of lack of integrity of the graft in microscopic tympanoplasties reported worldwide (18%), with the recent addition to the service of fibrin monomer, was necessary to evaluate if this material contributes to the integrity of the graft in microscopic tympanoplasty, as it has been reported in previous studies, so if there is found more integrity with this material, it can be recommended for routine use, improving the final prognosis of the patients.

Full Title of Study: “Effect of the Fibrin Monomer in the Integrity of the Graft During Tympanoplasty Compared With the Effect of the Hemostatic Sponge”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: February 2013

Detailed Description

Objective: Assess the effect of fibrin monomer in the integrity of the graft during tympanoplasties compared with the effect of the hemostatic sponge at the hospital of specialties Western Medical Center. Material and Methods: Clinical trial with single blind, parallel-groups and randomized assignation. There were included patients with a diagnosis of tympanic perforation, candidates for surgical treatment by performing only microscopic tympanoplasties, which fulfilled the selection criteria. The main variable of the study was the integrity of the graft. The statistical analysis was performed according to the nature of variables, for continuous data using measures of central tendency and dispersion and for the qualitative data with frequencies and percentages. To evaluate the effect of fibrin monomer relative to the hemostatic sponge, the data relating to the integrity of the graft between the groups were analyzed by chi-square.

Interventions

  • Procedure: Fibrin monomer
    • Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
  • Procedure: Hemostatic sponge
    • Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.

Arms, Groups and Cohorts

  • Active Comparator: Fibrin monomer
    • 40 patients, the material was ready to use in the case of the fibrin monomer it was maintained in cooling according to the indications of lab maintenance and it was taken out a few minutes before using the material to prepare it according to instructional use and thus ensure that the conditions of maintenance of equipment are appropriate to the best outcome with their use.
  • Placebo Comparator: Hemostatic sponge
    • 40 patients, the material was ready to use in the case of the hemostatic sponge was cut into small size, prepared and impregnated with hydrocortisone as in the standard procedure.

Clinical Trial Outcome Measures

Primary Measures

  • Integrity of the graft
    • Time Frame: every 4 weeks up to 3 months
    • Integrity of the graft (100%) was evaluated by standard audiologic and tympanometric parameters.

Secondary Measures

  • Complications
    • Time Frame: every 4 weeks up to 3 months
    • Adhesions, granulomas and hearing loss

Participating in This Clinical Trial

Inclusion Criteria

  • Patients diagnosed with tympanic perforation and with surgical indication of Tympanoplasty (without otorrhea for 6 months) Exclusion Criteria:

  • Background of tympanic perforation caused by allergic or pulmonary diseases including asthma and allergic rhinitis.

Gender Eligibility: All

Minimum Age: 16 Years

Maximum Age: 70 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • CLOTILDE FUENTES OROZCO
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: CLOTILDE FUENTES OROZCO, PhD – Instituto Mexicano del Seguro Social
  • Overall Official(s)
    • Clotilde Fuentes-Orozco, PhD, Study Director, Instituto Mexicano del Seguro Social
    • Luis-Humberto Govea-Camacho, PhD, Principal Investigator, Instituto Mexicano del Seguro Social

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.